December 14, 2017 07:15 AM EST
Financing

Re­lay grabs $63M to pay for a drug dis­cov­ery trip in­to the fourth di­men­sion

John Carroll

Editor & Founder

Two years af­ter Third Rock launched Re­lay Ther­a­peu­tics to ex­plore the drug dis­cov­ery po­ten­tial of watch­ing pro­teins in mo­tion, the Cam­bridge, MA-based biotech is back …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Out­look's shares crash as wet AMD drug flunks Phase 3 test

A service from the Financial Times